title: A Phase I trial of weekly docetaxel and topotecan for solid tumors.
abstract: OBJECTIVE
  Topotecan and docetaxel are active agents in the treatment of various malignant diseases. Both drugs cause dose-limiting hematologic toxicity. This study defines the maximum tolerated dose (MTD) and dose-limiting toxicity of weekly topotecan when administered in combination with docetaxel 25 mg/m(2) given day 1, 8,15 every 28 days.
  
  
  METHODS
  Thirteen patients were enrolled. Median age was 62 years. Majority of the patients had lung cancer.
  
  
  RESULTS
  The maximum tolerated dose was docetaxel 25 mg/m(2) and topotecan 3 mg/m(2) administered weekly. Dose-limiting toxicity was febrile neutropenia. Eight patients developed at least grade 3 neutropenia in all cycles. Non-hematologic toxicities were mild. No objective responses were noted. Two patients with non-small cell lung cancer had stable disease as a best response.
  
  
  CONCLUSIONS
  Combination docetaxel and topotecan given weekly is tolerable. The recommended phase II dose is docetaxel 25 mg/m(2) and topotecan 3 mg/m(2) day 1, 8, 15 every 28 days.
authors: Alvin J Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.
authors: Wan Teck
authors: WT
authors: Lim
authors: Maria Q
authors: MQ
authors: Baggstrom
authors: William
authors: W
authors: Read
authors: Paula M
authors: PM
authors: Fracasso
authors: Ramaswamy
authors: R
authors: Govindan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D019772:Topotecan